PAULA GASTON: Open Payments
NPI 1720363344 · PARIS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$675 in 26 payments from 10 companies in 2025. Trend: 2023 $484 · 2024 $249 · 2025 $675
Food & beverage: $675
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 6 | $191 |
| Novo Nordisk Inc | 1 | $113 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $109 |
| Janssen Biotech, Inc. | 3 | $67 |
| Lilly USA, LLC | 3 | $57 |
| IDORSIA PHARMACEUTICALS US INC | 2 | $40 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| Astellas Pharma US Inc | 1 | $23 |
| PFIZER INC. | 1 | $21 |
| GlaxoSmithKline, LLC. | 1 | $20 |
Products named: VRAYLAR, Ozempic, CAPLYTA, MOUNJARO, Quviviq, TECVAYLI, KEVEYIS, DARZALEX.
Industry payments across TX — which companies pay providers there.
